Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8619664 | 0.78 | TP53 (0.44) | TP53CALM1AOC3NR1H2NR1H3 | |
| SCHEMBL16378246 | 0.78 | TP53 (0.48) | TP53CALM1NR1H2NR1H3TSHR | |
| SCHEMBL1107767 | 0.78 | TP53 (0.48) | TP53CALM1NR1H2NR1H3TSHR | |
| SCHEMBL231005 | 0.78 | ESR1 (0.56) | TP53CALM1NR1H2NR1H3TSHR | |
| SCHEMBL8616442 | 0.75 | TP53 (0.46) | TP53CALM1NR1H2NR1H3TSHR | |
| SCHEMBL8620695 | 0.75 | CHRNB2 (0.52) | ALDH1A1TDP1 | |
| SCHEMBL8517700 | 0.74 | TP53 (0.43) | TP53CALM1NR1H2NR1H3TSHR | |
| SCHEMBL8381659 | 0.74 | TP53 (0.43) | TP53CALM1NR1H2NR1H3TSHR | |
| SCHEMBL2098666 | 0.74 | TP53 (0.43) | TP53CALM1NR1H2NR1H3TSHR | |
| SCHEMBL3406066 | 0.74 | TP53 (0.43) | TP53CALM1NR1H2NR1H3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0363284-B1 | Use of peptidase inhibitors for the preparation of medicaments useful for the treatment of strokes | MERRELL PHARMA INC (US) | 1997-05-14 | — | — | EP | claimed |
| US-20230132484-A1 | STERICALLY HINDERED PHOSPHINE-AMIDE SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230129371-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4126991-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | Dow Global Technologies LLC (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126992-A1 | STERICALLY HINDERED PHOSPHINE-AMIDE SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | Dow Global Technologies LLC (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021202722-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202714-A1 | STERICALLY HINDERED PHOSPHINE-AMIDE SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-0364344-B1 | Novel peptidase inhibitors | MERRELL PHARMA INC (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5736520-A | INHIBITING CALPAIN BY ADMINISTERING A DIPEPTIDE OF THE FORMULA BENZYLCARBONYLOXYVAL-NH-CH(-R2)-CHO WHERE R2 IS THE SIDE CHAIN OF PHE; ANTICARCINOGENIC,-ARTHRITIC AND CARDIOTONIC AGENTS; COAGULANTS; STROKE | MERRELL PHARMACEUTICALS INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0363284-B1 | Use of peptidase inhibitors for the preparation of medicaments useful for the treatment of strokes | MERRELL PHARMA INC (US) | 1997-05-14 | — | — | EP | disclosed |
| EP-0363284-A2 | Use of peptidase inhibitors for the preparation of medicaments useful for the treatment of strokes | MERRELL PHARMACEUTICALS INC. (US) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129371-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | PCNA, NIT2, MCM7 | TP53 1570/4885CALM1 4823/4885AOC3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.